腾博会官网·[中国]-诚信为本,专业服务!

VOLUNTARY ANNOUNCEMENT - UPDATE ON DEVELOPMENT PROGRESS OF MASH PRODUCTS "LANIFIBRANOR" AND "TQA2225"

VOLUNTARY ANNOUNCEMENT - DATA OF PHASE II CLINICAL STUDY OF KRAS G12C INHIBITOR "GARSORASIB TABLET (D-1553)" WILL BE PRESENTED AT 2024 AACR

VOLUNTARY ANNOUNCEMENT - DATA OF 5 STUDIES REGARDING "ANLOTINIB HYDROCHLORIDE CAPSULES" AND "TQB2916 (CD40 AGONIST)" WILL BE PRESENTED AT 2024 AACR

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 29 FEBRUARY 2024

NOTIFICATION OF BOARD MEETING

VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF THE NEW INDICATION APPLICATION FOR MARKETING OF ANLOTINIB HYDROCHLORIDE CAPSULES AND ANTI PD-L1 "BENMELSTOBART (TQB2450 INJECTION)"

VOLUNTARY ANNOUNCEMENT - ANTI PD-L1 “BENMELSTOBART (TQB2450 INJECTION)” INCLUDED IN PRIORITY REVIEW AND APPROVAL PROCEDURES

DISCLOSEABLE TRANSACTION - DISPOSAL OF EQUITY INTEREST IN CP QINGDAO